Li Pan1, Xiang Chen1,2, Shengling Fu1,3, Wenying Yu4, Chenglong Li5, Tiffany Wang1, Hui-Wen Lo6, Jiayuh Lin7. 1. Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA. 2. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. 3. Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 4. China Pharmaceutical University, Nanjing, China. 5. College of Pharmacy, University of Florida, Gainesville, FL, USA. 6. Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. 7. Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA. JLin@som.umaryland.edu.
Abstract
PURPOSE: Persistent STAT3 signaling is frequently detected in many cancer types including triple-negative breast cancer, and thus could potentially serve as a viable therapeutic target. We have designed a novel non-peptide compound LLY17 targeting STAT3 using Advanced Multiple Ligand Simultaneous Docking (AMLSD) methods. However, the efficacy of LLY17 has not been evaluated extensively in human and murine triple-negative breast cancer cells. In this study, we tested LLY17 in multiple human and murine triple-negative breast cancer cell lines. METHODS: Human triple-negative breast cancer MDA-MB-468, MDA-MB-231, SUM159, and BT-549 cells, and murine triple-negative breast cancer 4T1 cells were used to study the inhibition effects of LLY17. The inhibition of STAT3 activation of LLY17 was investigated using western blot analysis. Cell viability, apoptosis and migration assays were carried out by MTT assay, Caspase-3/7 assay and wound healing assay, respectively. A mammary fat pad syngeneic mouse model was used to evaluate the antitumor effect of LLY17 in vivo. RESULTS: LLY17 inhibited IL-6-mediated induction of STAT3 phosphorylation but had no effect on IFN-γ-induced STAT1 phosphorylation or EGF-induced ERK phosphorylation. LLY17 inhibited STAT3 phosphorylation and induced apoptosis in human and murine triple-negative breast cancer cells but exhibited minimal toxicity toward Luminal A subtype breast cancer MCF-7 cells. RNAi attenuation experiments supported the requirement of STAT3 for LLY17-mediated inhibition of cell viability in triple-negative breast cancer cells. In addition, LLY17 inhibited cell migration of human and murine triple-negative breast cancer cells. Furthermore, LLY17 suppressed tumor growth and STAT3 phosphorylation of triple-negative breast cancer cells in a mammary fat pad syngeneic mouse model in vivo. CONCLUSIONS: Together, our findings suggest that targeting persistent STAT3 signaling by novel small molecule LLY17 may be a potential approach for the therapy of triple-negative breast cancer.
PURPOSE: Persistent STAT3 signaling is frequently detected in many cancer types including triple-negative breast cancer, and thus could potentially serve as a viable therapeutic target. We have designed a novel non-peptide compound LLY17 targeting STAT3 using Advanced Multiple Ligand Simultaneous Docking (AMLSD) methods. However, the efficacy of LLY17 has not been evaluated extensively in human and murine triple-negative breast cancer cells. In this study, we tested LLY17 in multiple human and murine triple-negative breast cancer cell lines. METHODS:Human triple-negative breast cancerMDA-MB-468, MDA-MB-231, SUM159, and BT-549 cells, and murine triple-negative breast cancer4T1 cells were used to study the inhibition effects of LLY17. The inhibition of STAT3 activation of LLY17 was investigated using western blot analysis. Cell viability, apoptosis and migration assays were carried out by MTT assay, Caspase-3/7 assay and wound healing assay, respectively. A mammary fat pad syngeneic mouse model was used to evaluate the antitumor effect of LLY17 in vivo. RESULTS: LLY17 inhibited IL-6-mediated induction of STAT3 phosphorylation but had no effect on IFN-γ-induced STAT1 phosphorylation or EGF-induced ERK phosphorylation. LLY17 inhibited STAT3 phosphorylation and induced apoptosis in human and murine triple-negative breast cancer cells but exhibited minimal toxicity toward Luminal A subtype breast cancerMCF-7 cells. RNAi attenuation experiments supported the requirement of STAT3 for LLY17-mediated inhibition of cell viability in triple-negative breast cancer cells. In addition, LLY17 inhibited cell migration of human and murine triple-negative breast cancer cells. Furthermore, LLY17 suppressed tumor growth and STAT3 phosphorylation of triple-negative breast cancer cells in a mammary fat pad syngeneic mouse model in vivo. CONCLUSIONS: Together, our findings suggest that targeting persistent STAT3 signaling by novel small molecule LLY17 may be a potential approach for the therapy of triple-negative breast cancer.
Entities:
Keywords:
IL-6 signaling pathway; LLY17; STAT3; Small molecule inhibitor; Triple-negative breast cancer
Authors: Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Jacqueline C Lieblein; Sarah Ball; Brian Hutzen; A Kate Sasser; Huey-Jen Lin; Tim Hm Huang; Brett M Hall; Jiayuh Lin Journal: BMC Cancer Date: 2008-10-21 Impact factor: 4.430
Authors: Marjan Berishaj; Sizhi Paul Gao; Simi Ahmed; Kenneth Leslie; Hikmat Al-Ahmadie; William L Gerald; William Bornmann; Jacqueline F Bromberg Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: José A López-Mejía; Luis F Tallabs-Utrilla; Pablo Salazar-Sojo; Jessica C Mantilla-Ollarves; Manuel A Sánchez-Carballido; Leticia Rocha-Zavaleta Journal: Int J Mol Sci Date: 2022-08-05 Impact factor: 6.208
Authors: Sarah Q To; Rhynelle S Dmello; Anna K Richards; Matthias Ernst; Ashwini L Chand Journal: Cancers (Basel) Date: 2022-01-15 Impact factor: 6.639